GSK Buys Nuvalent for $10.6 Billion to Expand Cancer Line - Bloomberg.com

GSK Buys Nuvalent for $10.6 Billion to Expand Cancer Line  Bloomberg.com

GSK in talks to buy cancer biotech Nuvalent for more than $9bn

A deal will rank as one of UK drugmaker’s biggest as biotech M&A activity has enjoyed an upswing this year

GSK to buy US cancer treatment firm Nuvalent for $10.6bn

British drugmaker’s new chief executive Luke Miels announces one of its biggest deals Business live – latest updates GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications. The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer. Continue reading...

By Julia Kollewe

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.

GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down

U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.

By Steve Goldstein

GSK to buy US lung cancer drug specialist Nuvalent for £8bn

The acquisition is thought to be GSK’s biggest deal in more than a decade.

By Holly Williams

Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK